Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Gayle, Grigson"'
Autor:
Paul A. Godley, Karla Morris, W. Kimryn Rathmell, Dominic T. Moore, Daniel J. George, Gayle Grigson, Raj S. Pruthi, Jeffrey M. Crane, Eric Wallen, William Y. Kim, Catharine Watkins, Young E. Whang, Andrew J. Armstrong
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 31:82-86
Objectives Epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases may be involved in activation of androgen receptor and progression of prostate cancer. They represent potential therapeutic targets in prostate cancer. Lapatinib is an oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7575a930672bdf0632759cece83c58
https://doi.org/10.1016/j.urolonc.2010.09.018
https://doi.org/10.1016/j.urolonc.2010.09.018
Autor:
Eric Wallen, Young E. Whang, Catharine Watkins, Paul A. Godley, Raj S. Pruthi, W. Kimryn Rathmell, Maria Q. Baggstrom, Julian G. Rosenman, William Y. Kim, Lav K. Goyal, Gayle Grigson
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 29:608-613
Background Patients with locally advanced or organ confined, high risk, prostate cancer are at significant risk of having disease recurrence despite definitive local therapy. We evaluated the 2-year progression-free survival of subjects treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f41044d3f30d0ddcab5c3fa388937af
https://doi.org/10.1016/j.urolonc.2009.09.012
https://doi.org/10.1016/j.urolonc.2009.09.012
Autor:
Angela B. Smith, Raj S. Pruthi, Young E. Whang, Gayle Grigson, Julia R. Fielding, Samuel A. Heathcote, Eric Wallen, Paul A. Godley, W. Kim Rathmell, William Y. Kim, Matthew E. Nielsen, Heather Schultz
Publikováno v:
BJU International. 106:349-354
Study Type – Therapy (cohort) Level of Evidence 2b OBJECTIVE To evaluate the clinicopathological efficacy of neoadjuvant erlotinib (an epidermal growth factor receptor, EGFR, inhibitor) for invasive bladder cancer in patients undergoing radical cys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03d5abf0b430b389c81a68fad2e899cd
https://doi.org/10.1111/j.1464-410x.2009.09101.x
https://doi.org/10.1111/j.1464-410x.2009.09101.x
Autor:
W. Kimryn Rathmell, Christine B. Marino, T. Richmond, Jared Gollob, Catharine Watkins, Gayle Grigson, Lin Gu, Bercedis L. Peterson, Elizabeth K. Miller, John J. Wright
Publikováno v:
Journal of Clinical Oncology. 25:3288-3295
Purpose We undertook this study to determine the activity and tolerability of sorafenib administered with interferon alfa-2b (IFN-α-2b) as first- or second-line therapy in metastatic renal cell cancer (RCC). Patients and Methods Between November 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52c563ca4d5f89ec1183433f7d900de
https://doi.org/10.1200/jco.2007.10.8613
https://doi.org/10.1200/jco.2007.10.8613
Autor:
Raj S. Pruthi, Cathy Watkins, Culley C. Carson, J. Eric Derksen, Eric Wallen, Gayle Grigson, Dominic T. Moore
Publikováno v:
Clinical Cancer Research. 12:2172-2177
Objectives: Recent evidence has shown that cyclooxygenase-2 (COX-2) inhibitors have potent antitumor activity in prostate cancer both in vitro and in vivo. However, human trials are absent. This study evaluated the efficacy of the COX-2 inhibitor cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::529ebdcf09a7cf262fae274a5a757924
https://doi.org/10.1158/1078-0432.ccr-05-2067
https://doi.org/10.1158/1078-0432.ccr-05-2067
Autor:
Raj S, Pruthi, Matthew, Nielsen, Samuel, Heathcote, Eric M, Wallen, W Kim, Rathmell, Paul, Godley, Young, Whang, Julia, Fielding, Heather, Schultz, Gayle, Grigson, Angela, Smith, William, Kim
Publikováno v:
BJU international. 106(3)
To evaluate the clinicopathological efficacy of neoadjuvant erlotinib (an epidermal growth factor receptor, EGFR, inhibitor) for invasive bladder cancer in patients undergoing radical cystectomy (RC) as despite definitive surgical therapy, only half
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c4ced49f604dd8de5ba55e2b3470531
https://pubmed.ncbi.nlm.nih.gov/20089114
https://pubmed.ncbi.nlm.nih.gov/20089114
Autor:
Young E. Whang, C. Lance Cowey, William Y. Kim, Dominic Moore, Gayle Grigson, Matthew E. Nielsen, Cathy Watkins, Jeffrey M. Crane, Keith V. Nance, Paul A. Godley, Chirag Amin, Eric Wallen, Mark Jalkut, Julia R. Fielding, W. Kimryn Rathmell, Raj S. Pruthi
Purpose The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5bf22495e8619a5f7cb8de436609da
Publikováno v:
Journal of Clinical Oncology. 26:11076-11076
11076 Background: Despite surgical therapy, only 50% of patients undergoing radical cystectomy for transitional cell carcinoma (TCC) of the bladder will experience long-term disease-free survival. ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8d265320fd94a9b61549dcc0e959bb6
https://doi.org/10.1200/jco.2008.26.15_suppl.11076
https://doi.org/10.1200/jco.2008.26.15_suppl.11076
Autor:
Cathy Watkins, Karla Morris, Jeffrey M. Crane, Cassandra Moore, Andrew J. Armstrong, Wendy Kimryn Rathmell, Daniel J. George, Gayle Grigson, Young E. Whang, Paul A. Godley
Publikováno v:
Journal of Clinical Oncology. 26:16037-16037
16037 Background: Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases represent potential targets in prostate cancer. HER2 promotes progression of prostate cancer to the hormone refractory stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12945b37f10fa19a290007ec007c90d5
https://doi.org/10.1200/jco.2008.26.15_suppl.16037
https://doi.org/10.1200/jco.2008.26.15_suppl.16037
Autor:
John J. Wright, Cathy Watkins, J. Jones, Wendy Kimryn Rathmell, Jared Gollob, Bercedis L. Peterson, Gayle Grigson, T. Richmond
Publikováno v:
Journal of Clinical Oncology. 24:4538-4538
4538 Background: Sorafenib is a VEGFR/PDGFR-β/Raf inhibitor that improves PFS in metastatic RCC with a RR of 2%. IFN-α improves OS in RCC with a RR of ≈10%. Methods: Based on the activity of sorafenib and IFN-α in RCC, a phase II combination tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53cc7003265cee5aa6df2a426c835d34
https://doi.org/10.1200/jco.2006.24.18_suppl.4538
https://doi.org/10.1200/jco.2006.24.18_suppl.4538